Dr Albanese is a strong addition to Motif’s executive team. His real world experience in working amongst large hospital groups will prove useful in the future commercialisation of Motif’s flagship antibiotic iclaprim.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Northland Capital Partners Morning Report
- Published:
05 May 2017 -
Author:
Vadim Alexandre -
Pages:
8
Dr Albanese is a strong addition to Motif’s executive team. His real world experience in working amongst large hospital groups will prove useful in the future commercialisation of Motif’s flagship antibiotic iclaprim.